RIGEL PHARMACEUTICALS INC Form 8-K February 14, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 8, 2013

RIGEL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

0-29889 (Commission File No.)

94-3248524

(IRS Employer Identification No.)

1180 Veterans Boulevard

South San Francisco, CA 94080

(Address of principal executive offices)


94080

(Zip Code)

Registrant s telephone number, including area code: (650) 624-1100

Not Applicable

(Former name or former address, if changed since last report)



- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.			
(e)			
2013 Cash Incentive Plan			
On February 8, 2013, the Board of Directors (the <u>Board</u>) of Rigel Pharmaceuticals, Inc. (the <u>Company</u>) approved the 2013 Cash Incentive Plan (the <u>Incentive Plan</u>), pursuant to which the Company's named executive officers and other employees may become entitled to cash bonus payments based on attainment of specified corporate performance goals. A copy of the Incentive Plan is attached as Exhibit 10.34 hereto and is incorporated herein by reference.			
Item 9.01. Financial Statements and Exhibits.			
(d)	Exhibits.		
Exhibit 10.34	2013 Cash Incentive Plan	Description	
		2	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 14, 2013 RIGEL PHARMACEUTICALS, INC.

By: /s/ Dolly A. Vance Dolly A. Vance

Executive Vice President, General Counsel and Corporate

Secretary

3

EXHIBIT INDEX

Exhibit	Description
10.34	2013 Cash Incentive Plan

4